Pharvaris NV Aktie News

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks ...

Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million.

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

Pharvaris stock surged Wednesday — and KalVista reversed higher — on promising test results for an HAE treatment.

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p

Increased Pharvaris stake by 500,000 shares, with a net position value change of $67.83 million Transaction represented 0.3% of General Atlantic, L.P.'s 13F reportable assets under management (AUM) Post-trade holding: 8,031,252 shares valued at $200.38 million The Pharvaris position now accounts for 6.0% of fund AUM, which places it outside the fund's top five holdings

I initiate Pharvaris with a buy rating and $40 target price, driven by its differentiated oral bradykinin B2 antagonist franchise for HAE. PHVS's late-stage pipeline targets both on-demand and prophylactic HAE treatment, with pivotal phase 3 data expected by year-end 2025. Deucrictibant's validated mechanism, strong phase 2 results, and regulatory precedent de-risk the upcoming phase 3 readout,...

Sold 122,106 shares of Pharvaris N.V, reducing position value by $21.23 million Post-trade holding: 3,181,275 shares valued at $79.37 million Position now accounts for 5.27% of AUM, ranking as the fund's 4th-largest holding